



Understanding the impact of cancer diagnosis and treatment on everyday life

12 MONTH ENDOMETRIAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the 6 month CRF when completing this 12 month CRF: please complete any additional treatment details that were not captured at 6 months (for example, additional treatments, or end dates of those ongoing at 6 months)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID /									
Participant's date of birth d d	m m	У	/ y	У					
Has the participant been tested for Lyn	ch Syndro	me (pl	ease	tick	k or	ne b	ox)		
Yes (already recorded in previous CRF)									
Yes (but not recorded in previous CRF)									
No									
Unknown									
	in previou	ıs CRF)	" to	the	e ab	ove	ques	tion,	
Positive for Lynch syndrome	in previou	ıs CRF)	" to	the	e ab	ove	ques	tion,	
Negative for Lynch syndrome	in previou	ıs CRF)	" to	the	e ab	ove	ques	tion,	
Positive for Lynch syndrome	in previou	us CRF)	" to	the	e ab	ove	ques	tion,	
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain									ne
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain Awaiting result Has the participant had any other gene									ne
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain Awaiting result Has the participant had any other generox)									ne
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain Awaiting result Has the participant had any other gene box) Yes (already recorded in previous CRF)									ne

If you answered "Yes (but not recorded in previous CRF)" to the above question, please provide some information about the participant's other genetic test(s) by completing the table(s) overleaf

Participant's Study ID /		
Name of genetic test for cancer (1)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	
Name of genetic test for cancer (2)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	
Has the participant developed any NEW co- the baseline or 6 month CRFs)? (please tick overleaf)		
Myocardial infarct		
Angina/coronary artery disease		
Congestive Heart Failure		
Cardiac Arrythmias		
Hypertension		
Venous Disease (PE/DVT)		

HORIZONS; 12 month Case Report Form; Endometrial. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)

Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)

Peripheral Arterial Disease

Participant's Study ID / /	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	
Clinical diagnosis of depression	
Other Psychiatric Diagnosis (eg. schizophrenia, bipolar disorder etc.)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder,	
polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	

Participant's Study ID	/	' <i> </i>	

What treatments has the participant received **since those captured at 6 months**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing at 6 months (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Surgery	Please give details below of surgery (e.g. surgery for cancer, palliative surgery)		// 20		
Combined Chemo- radiotherapy	Combined chemo-radiotherapy Please also tick the boxes below/ overleaf to indicate which treat- ments were combined. If the combined treatments are not mentioned below/overleaf, please give details on line		// 20	// 20	
Chemotherapy	Carboplatin		// 20	//20	
	Carboplatin with paclitaxel		// 20	//20	
	CAP: cyclophosphamide, doxorubicin and cisplatin/carboplatin		// 20	// 20	
	Other chemotherapy (please describe)		// 20	// 20	
	Chemotherapy number of cycles	(please er	nter on line)		
Radiotherapy	External radiotherapy		//20	// 20	
	Combined external radiotherapy and brachytherapy (please also complete brachytherapy details overleaf)		// 20	// 20	
	Number of radiotherapy fractions	s (please e	enter on line)		
	Dose for each radiotherapy fraction	on (please	enter on line)		

HORIZONS; 12 month Case Report Form; Endometrial. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Participa	nt's Study ID		/		
Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of oth- er treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of trea ment was not completed as planned, please give a reason why
Radiotherapy (cont.)	Brachytherapy LOW dose rate		// 20	// 20	
	Brachytherapy HIGH dose rate		//20	// 20	
	Brachytherapy PULSED dose rate		// 20	// 20	
Additional Treatment	If any additional treatment has been given please describe		// 20	// 20	
one box)	rticipant had a local red Yes cipant has had a local r	No		Jnknown	
_	earticipant's diagnosis on the metastatic disease? (plo			nas there been a	ny evidence
	Yes	No	, , , , , , , , , , , , , , , , , , ,	nknown	
If you have disease dia	answered "yes" to the grosed:	above o	uestion, on wh	nat date was the	metastatic
Please prov	vide details of the site(s) of dista	ant metastatic	disease:	

Participant's Study ID /	
Is the participant pre or post menopause	? (please tick one box)
Pre menopause	
Post menopause	
Unknown	
Is the participant taking part in a clinical t	rial? (please tick one box)
Yes No	Unknown
If you answered "yes" to the above quest trial the participant is taking part in Name of clinical trial	ion, please give the NAME of the clinical
Since the participant's diagnosis of endor with another new primary cancer? (pleas	
Yes No	Unknown
If you answered "yes" to the above quest about the participant's new cancer diagnostics.	
Type of cancer	
Date of diagnosis	// 20
Treatment received	

Date treatment ended (if finished)

_/__/20___

What type of follow-up care is the participant receiving? (please tick ONE box)	
Routine/regular hospital clinic based follow-up (medical or nurse led,	
face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up	
(PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were	
they discharged to this?	
Has the participant been referred to any of the following convices and/or had a	I I aliatia
Has the participant been referred to any of the following services and/or had a Needs Assessment? (please tick all that apply)	HOIISLIC
Needs Assessment: (piedse tiek an that apply)	
Participant has been referred to palliative care services	
Participant has been referred to psychological services	
If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)	
Participant has been referred to community services	
Participant has been referred for treatment related problems (e.g. urology,	
gastroenterology) If ticked, please provide more details below:	

Participant's Study ID

Participant has had an HNA (holistic needs assessment)

Participant's Study ID / /
If the participant has died please give the date and cause of death:
Participant's date of death d d / m m / y y y y
Cause of participant's death
1) a)
1) b)
1) c)
2)
Cause of death not known
Please add your name and signature and the date that you completed this CRF
Name Signature
Date CRF completed dd / m m / y y y y